Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
efdamrofusp alfa
- Development stage
- Phase 3
- Lead developer
- Suzhou Innovent Biologics
- Modality
- Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes
- Administration
- Ophthalmic
01
Overview
Efdamrofusp alfa is a recombinant, fully human bispecific fusion protein that acts as both an angiogenesis inhibitor and a complement activation inhibitor. It is designed to neutralize vascular endothelial growth factor (VEGF) isoforms and the complement components C3b/C4b, thereby inhibiting VEGF-mediated angiogenesis and complement activation. The drug is being developed primarily for ophthalmic indications such as neovascular (wet) age-related macular degeneration (nAMD), with additional research in diabetic macular edema and other complement-related ocular conditions. Efdamrofusp alfa has demonstrated noninferiority to aflibercept in improving best-corrected visual acuity in nAMD patients, with a similar safety profile[1][2][3][5][6].
- Other names
- efdamrofusp alfaIBI302IBI-302IBI 302
02
Targets
C3b (Complement Component 3b)VEGFA (Vascular endothelial growth factor A)
Beyond the preview
Go deeper on efdamrofusp alfa.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on efdamrofusp alfa.